Our results revealed that (1) serum ADMA concentration was elevated in patients with colon cancer; (2) ADMA treatment attenuated SS-induced apoptosis in LoVo cells via suppression of the Fas/JNK pathway; and (3) ADMA ameliorated doxorubicin-induced cell death and inhibited activation of Fas and JNK in LoVo cells. This evidence concerns the gene FAS and colonic neoplasm.